OS Therapies Net Income

The latest net income for OSTX is $-37B as of June 2026. That compares with $-3.9B in the prior-year period — down 861.8% year over year. That is below the sector sector average of $89M. Investors often review this figure alongside OS Therapies's historical trend and sector peers before judging valuation or financial health.

Over the past year, OSTX's net income moved from $-3.9B to $-37B — a 861.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in OS Therapies's operating scale or balance-sheet position.

Against its sector companies, OSTX currently prints $-37B for net income, while the sector average sits near $89M. That is roughly 42140.6% below the sector mean. Large gaps often invite a closer look at OS Therapies's growth, margins, and balance sheet.

A net income figure of $-37B for OSTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $89M. Explore the charts below for those layers of context.

After noting OSTX's net income ($-37B), review year-over-year change from $-3.9B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.